Micro-Cap Stock IBio Doubles On Wednesday - Here's Why
Micro-Cap Stock IBio Doubles On Wednesday - Here's Why
iBio Inc (NYSE:IBIO) shares are surging after the company entered into a collaboration agreement with AstralBio Inc. on Wednesday to discover, engineer, and develop antibodies to treat obesity and other cardiometabolic conditions.
iBio Inc.（紐約證券交易所代碼：IBIO）週三與AstralBio Inc.簽訂了合作協議，旨在發現、設計和開發治療肥胖和其他心臟代謝疾病的抗體，此後，該公司股價飆升。
The shares are trading over 100% with a strong session volume of 38.98 million compared to an average volume of average Volume 106.958K as per data from Benzinga Pro.
根據Benzinga Pro的數據，這些股票的交易量超過100％，強勁的交易量爲3,898萬股，而平均成交量爲106.958萬。
This micro-cap biotech player is valued at $4 million, with an enterprise value of $17.7 million.
這家微型生物技術公司的估值爲400萬美元，企業價值爲1770萬美元。
Tuesday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital, and other institutional investors.
星期二，iBio 宣佈了 完成了與 ADAR1 資本管理公司、Lynx1 Capital Management、Ikarian Capital和其他機構投資者的1500萬美元私募融資。
The company will use some of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
該公司將把部分淨收益用於支持新的合作伙伴關係，例如與AstralBio的合作。
As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four targets for cardiometabolic disease, of which AstralBio may continue the pre-clinical development and deploy its proven drug development expertise to advance candidates to an Investigational New Drug (IND) application.
作爲合作的一部分，iBio已授予其人工智能技術的獨家許可，用於識別和設計心臟代謝疾病的四個靶標，AstralBio可能會繼續進行臨床前開發，並利用其成熟的藥物開發專業知識來推動候選藥物進入研究性新藥（IND）的申請。
iBio has the exclusive option to license three cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.
iBio擁有向AstralBio許可三種心臟代謝靶標的獨家選擇權，並將在行使後獲得開發、製造和商業化這些靶標的權利。
As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a lead program focused on targeting the transforming growth factor beta (TGFb) superfamily for the treatment of muscle wasting and obesity.
由於這種合作，iBio和AstralBio已同意啓動一項主要項目的開發，重點是針對轉化生長因子β（TGfB）超家族來治療肌肉萎縮和肥胖。
Upon mutual consent, the parties may expand the collaboration to include additional targets in other fields.
經雙方同意，各方可以擴大合作，將其他領域的其他目標包括在內。
"We are confident our AI-enabled technology is exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic space," said iBio's CEO and Chief Scientific Officer, Martin Brenner.
iBio首席執行官兼首席科學官馬丁·布倫納表示：“我們相信，我們的人工智能技術完全有能力開發針對心臟代謝領域挑戰性靶標的抗體。”
Price Action: IBIO shares are up 147.80% at $2.84 on the last check Wednesday.
價格走勢：在週三的最後一次支票中，IBIO股價上漲147.80％，至2.84美元。
Photo via Shutterstock
照片來自 Shutterstock
譯文內容由第三人軟體翻譯。